POMT1

Across TCGA pan-cancer cohorts, POMT1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated POMT1 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher POMT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated POMT1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where POMT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	III,IV	0.583	0.986	.010	10	view →
CCRCC	DFS	Median	All	1.000	0.680	.013	4	view →
LUAD	DFS	Quartile	III,IV	0.278	0.875	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

POMT1–LSCC (OS)

Open the LSCC breakdown →